•  
  •  
  •  
  •  

2026-07-20 11:14:19

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • JioStar Reports Strong Q1 FY27 Performance: EBITDA Operations Up 30.7% as JioHotstar Hits Record 530 Million MAUs
  • Reliance Retail Ventures Limited Reports Q1 FY27 Gross Revenue of ₹90,408 Crore: Digital Commerce Surges Across Consumption Baskets
  • Jio Platforms Reports Surge in Q1 FY27 Net Profit to ₹7,764 Crore: EBITDA Margins Expand to Record 53.3%
  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality

Keywords Selected:  Inspection

Stock Report

  • USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
  • Completion of US-FDA Inspection at Sterile Product Division facility at Bengaluru
  • US FDA inspection at Glenmark Pharmaceuticals Ltd's manufacturing facility in Goa, India
  • Completion of US FDA Inspection at Auroactive Pharma Pvt Ltd
  • Qualitek Labs Ltd receives NABCB Accreditation under ISO/IEC 17020:2012 for Inspection Services
  • Concord Biotech Ltd successfully completes PPB and NDA inspection
  • Concord Biotech Ltd completes ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility
  • USFDA inspection at Cipla Ltd's manufacturing facility in Verna, Goa, India
  • Wanbury's Tanuku unit successfully completes Quality Inspection by TGA
  • US FDA Inspection at Alkem Laboratories Ltd's CRO facility located at Taloja
  • USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad
  • US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Amaliya, Daman
  • Wanbury's Patalganga site completes MFDS inspection successfully
  • Solara announces successful closure of US FDA inspection of its Puducherry Facility with continued state of cGMP compliance
  • USFDA inspection at Rubicon Research Ltd's R&D Facility
  • Ajanta Pharma Ltd updates on USFDA inspection
  • USFDA Inspection at Innoxel Lifesciences Private Limited
  • USFDA inspection at Somerset facility of Lupin Ltd
  • USFDA inspection at Cipla Ltd's manufacturing facility in Goa, India
  • Morepen Secures Fourth Consecutive USFDA Inspection with Zero Observations
  • Granules Life Sciences Receives VAI Classification following US FDA Inspection
  • Completion of US-FDA Inspection at Unit-IV, Tarapur of Aarti Pharmalabs Limited
  • Unit-IV of APL Healthcare Ltd classified as VAI by the US FDA
  • Completion of US FDA Inspection at Unit I of Eugia Pharma Specialities Ltd., Shameerpet

Latest Post

  • JioStar Reports Strong Q1 FY27 Performance: EBITDA Operations Up 30.7% as JioHotstar Hits Record 530 Million MAUs
  • Reliance Retail Ventures Limited Reports Q1 FY27 Gross Revenue of ₹90,408 Crore: Digital Commerce Surges Across Consumption Baskets
  • Jio Platforms Reports Surge in Q1 FY27 Net Profit to ₹7,764 Crore: EBITDA Margins Expand to Record 53.3%
  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025